Immix Biopharma

Company snapshot

Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases. Our lead cell therapy is FDA IND cleared next generation CAR-T NXC-201, currently being evaluated in our ongoing Phase 1b/2 NEXICART-1 (NCT04720313) clinical trial, initiated in February 2021. NXC-201 has the potential to be the

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 US patent(s) indexed to this assignee profile.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Immix Biopharma. Not investment advice.

• Peer + 0 momentum

  BEONE MEDICINES AUS

  TA overlap score 40

• Peer + 0 momentum

  Eikon Therapeutics

  TA overlap score 23

Recent activity

Latest pipeline, patent, and corporate events for Immix Biopharma.

1. Jun 5, 2026 Clinical update

   NXC-201 CAR-T — Phase 2

2. Jun 5, 2026 Clinical update

   IMX-110 combined with Tislelizumab — Phase 2

3. May 23, 2026 Clinical update

   Imx-110 — Phase 2

4. Nov 21, 2023 Patent grant

   Micelle constructs comprising curcumin

5. Dec 5, 2017 Patent grant

   Cancer therapeutics

View all clinical trial activity →

• What is Immix Biopharma?

  Immix Biopharma is a biotech organization headquartered in Los Angeles, USA. It trades on NYSE under ticker IMMX. Primary therapeutic focus areas include Advanced Solid Tumor, Solid Tumor, Adult, Light Chain (AL) Amyloidosis. NovaPharmaNews links 3 clinical program(s), 0 drug pro

• Is Immix Biopharma publicly traded?

  Yes. Immix Biopharma is listed with ticker IMMX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Immix Biopharma develop or market?

  We link 2 drug profile(s) where Immix Biopharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/immix-biopharma#company-drugs.

• What are the latest developments for Immix Biopharma?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Immix Biopharma focus on?

  Immix Biopharma focuses on Advanced Solid Tumor, Solid Tumor, Adult, Light Chain (AL) Amyloidosis based on our analysis of their pipeline programs and drug development activities.